ATSN-401, Atsena Therapeutics’ investigational gene therapy for Stargardt disease, has [...]

FORE Biotherapeutics has completed target enrolment in the primary central [...]

Healome Therapeutics has raised £2 million in seed funding to [...]

EnteroBiotix has dosed the first patient in its Phase 2b [...]

bit.bio has launched two cell culture media kits designed to [...]

ReproNovo has dosed the first participant in a European Phase [...]

Novartis has agreed to acquire UK biotech Myricx Bio for [...]

The first patients have been dosed with MP0712, a DLL3-targeted [...]

CONNECTA Therapeutics will present preclinical data supporting its Phase 2a [...]

Lonza has acquired the rights to Nona Biosciences’ transferrin receptor [...]